Compare D Wave Quantum Inc (QBTS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D Wave Quantum Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? D Wave Quantum Inc trades at $17.52 (market cap $6.59B), while Vertex Pharmaceuticals Incorporated trades at $472.92 (market cap $122.33B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.6× D Wave Quantum Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| QBTS | VRTX | |
|---|---|---|
Market Cap | $6.59B | $122.33B |
Sector | Technology | Health |
52-Week High | $44.78 | $529.59 |
52-Week Low | $12.98 | $366.54 |
Enterprise Value | $6.05B | $117.07B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
